Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02147132 · ClinicalTrials.gov registry record · Phase 4
Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients
A Phase 4 study, sponsored by University of Cincinnati.
- Terminated
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT02147132 is a Phase 4 study that was terminated before completion, run by University of Cincinnati. The registered enrollment target is 7 participants.
The verdict
NCT02147132, a Phase 4 study, was terminated before completion, sponsored by University of Cincinnati.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
The objective is to provide a preliminary test of the ability of two pharmacological treatments, the nicotine nasal spray and varenicline, relative to placebos, to reduce smoking during the 4 hours following methadone dosing.
Interventions
- DRUG Varenicline
- DRUG Placebo Nasal Spray
- DRUG Nicotine Nasal Spray
- DRUG Placebo Varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-08-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02147132
The ClinicalTrials.gov registry entry for NCT02147132 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Varenicline is the first listed.
NCT02147132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02147132 about?
NCT02147132 is a clinical study titled "Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients". The objective is to provide a preliminary test of the ability of two pharmacological treatments, the nicotine nasal spray and varenicline, relative to placebos, to reduce smoking during the 4 hours following methadone dosing.
What is the current status of trial NCT02147132?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2016-03. Estimated completion is 2017-08-25.
What interventions are being tested in trial NCT02147132?
The interventions under investigation include: Varenicline (DRUG), Placebo Nasal Spray (DRUG), Nicotine Nasal Spray (DRUG), Placebo Varenicline (DRUG).
Who is sponsoring clinical trial NCT02147132?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.